1. ɽ����ѧ����ʡ��ҽԺ
2. ɽ����ѧ����ʡ��ҽԺƤ����

ҩ����ҩ��ͨ��ע�䡢�ڷ��������;����������������Ƥ���Ĥ��Ӧ�����ٴ����ֶ��ֶ������������Ʒdz����ӡ��о���ʾ��ϸ������Tϸ�������������ҩ��ķ�����ҩ�����֯����ı���Ҫ����Ϊ��Ƥ���ˣ������о����֣���Ƥ��Tϸ����ҩ��ı�Ƥ�����з�����Ҫ���ã�������Ƥ��Tϸ��������͡����ܡ�����ء�ЧӦ;��������ҩ���е����á�

Drug eruption, a mucocutaneous reaction following the entry of drugs into body through injection, oral administration or inhalation, has various clinical manifestations with complex pathogenesis. Recent studies suggest that cytotoxic T lymphocytes take part in the pathogenesis of many kinds of drug eruption. Histologically, drug eruption is characterized mainly by epidermal injury, and more and more evidence has suggested that epidermal T lymphocytes play a vital role in epidermal injury in drug eruption. This paper presents a concise description on the epitope, function, activation modulation, action pathway of epidermal T lymphocytes and their effect in drug eruption.

ɽ��ʡҽҩ�����Ƽ���չ�ƻ�

1. Clark RA, Chong B, Mirchandani N, et al. The vast majority of CLA+ T cells are resident in normal skin. J Immunol. 2006, 176(7): 4431-4439. 2. Spetz AL, Strominger J, Groh-Spies V. T cell subsets in normal human epidermis. Am J Pathol.1996, 149(2): 665-674. 3. Shiohara T, Mizukawa Y, Teraki Y. Pathophysiology of fixed drug eruption: the role of skin-resident T cells. Curr Opin Allergy Clin Immunol. 2002, 2(4): 317-323. 4. Shiohara T, Moriya N. Epidermal T cells: their functional role and disease relevance for dermatologists. J Invest Dermatol. 1997, 109(3): 271-275. 5. Shiohara T, Mizukawa Y. The immunological basis of lichenoid tissue reaction. Autoimmun Rev. 2005, 4(4): 236-241. 6. Lerch M, Pichler WJ.The immunological and clinical spectrum of delayed drug-induced exanthems.Curr Opin Allergy Clin Immunol,2004, 4(5): 411-419. 7. Komatsu T, Moriya N, Shiohara T. T cell receptor (TCR) repertoire and function of human epidermal T cells: restricted TCR V alpha-V beta genes are utilized by T cells residing in the lesional epidermis in fixed drug eruption. Clin Exp Immunol. 1996, 104(2): 343-350. 8. Mizukawa Y, Yamazaki Y, Teraki Y, et al. Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption. Am J Pathol. 2002, 161(4): 1337-1347. 9. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potential role of cytokines in toxic epidermal necrolysis. J Invest Dermatol. 2004, 123(5): 850-855. 10. Marzano AV, Frezzolini A, Caproni M, et al. Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunopathol Pharmacol. 2007, 20(3): 557-566. 11. Roujeau JC, Gélard K, Bensussan A. Epidermal necrolysis: mechanisms of keratinocyte apoptosis. Med Sci (Paris). 2006, 22(2): 188-191. 12. Yawalkar N. Drug-induced exanthems. Toxicology. 2005, 209(2): 131-134. 13. Yawalkar N, Egli F, Hari Y, Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy. 2000, 30(6): 847-855. 14. Czarnobilska E, Obtu?owicz K, Wso?ek K. Type IV of hypersensitivity and its subtypes. Przegl Lek. 2007, 64(7-8): 506-508. 15. Schmid S, Kuechler PC, Britschgi M, et al. Acute generalized exanthematous pustulosis: role of cytotoxic T cells in pustule formation. Am J Pathol 2002, 161: 2079–2086. 16. Naisbitt DJ, Britschgi M, Wong G, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol. 2003, 63: 732–741. 17. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis.J Am Acad Dermatol. 2007, 56(2): 181-200. 18. Teraki Y, Shiohara T. Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization. Dermatology. 2004, 209(1): 29-32. 19. Azukizawa H, Sano S, Kosaka H, Prevention of toxic epidermal necrolysis by regulatory T cells. Eur J Immunol. 2005, 35(6): 1722-1730. 20. Takahashi R, Kano Y, Yamazaki Y, et al. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol. 2009, 182(12): 8071-8079.